High-Density Lipoprotein Cholesterol in HIV-Infected Patients: Evidence for an Association with HIV-1 Viral Load, Antiretroviral Therapy Status, and Regimen Composition
Authors:
- 1 July 2008
- journal article
- research article
- Published by SAGE Publications in AIDS Patient Care and STDs
- Vol. 22 (7) , 569-575
Abstract
Low high-density lipoprotein-cholesterol (HDL-C) levels have been associated with cardiovascular risk in non-HIV populations. Limited information exists on the prevalence of low HDL-C in HIV- infected patients and related factors remain largely unknown. The aims of this study were to estimate the prevalence and characteristics of low HDL-C levels in HIV-infected patients. A cross-sectional study was performed in consecutive HIV-infected patients cared for in an outpatient HIV clinic on the Mediterranean coast of Spain during a 2-month period (September 15, 2003 to November 15, 2003). HDL-C levels below 40 mg/dL were considered low. We analyzed data from 219 patients, 167 of whom were on antiretroviral therapy. The majority (45.20 %) were on non-nucleoside reverse transcriptase inhibitors (NNRTI); 22.83 % were on treatment with protease inhibitors. The prevalence of low HDL-C levels was 44.74 % (98 of 219 patients). In multivariate analysis, hypertriglyceridemia (triglycerides >150 mg/dL; odds ratio [OR], 5.65; 95% confidence interval [CI], 2.85–11.23; p = 0.0001), HIV-1 RNA viral load greater than 50 copies per milliliter (OR, 3.15; 95% CI, 1.63–6.109; p = 0.001) and antiretroviral therapy with regimens other than NNRTIs-based regimens (OR, 2.17; 95% CI, 1.12–4.16; p = 0.021) were associated with low HDL-C levels. These data indicate that prevalence of low HDL-C among HIV-infected patients from this cohort was very high. Low HDL-C was related to triglyceride levels, HIV-1 RNA viral load and antiretroviral therapy composition. Undetectable viral load and treatment with NNRTIs are protective factors, whereas hypertriglyceridemia is directly associated with low HDL-C levels.Keywords
This publication has 32 references indexed in Scilit:
- The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patientsAtherosclerosis, 2007
- Resistencia insulínica en pacientes con infección por el VIH en tratamiento prolongado con efavirenz, lopinavir/ritonavir y atazanavirMedicina Clinica, 2007
- Alteraciones lipídicas y riesgo cardiovascular asociado a la terapia antirretroviralEnfermedades Infecciosas y Microbiología Clínica, 2006
- HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatmentMetabolism, 2006
- Combination Antiretroviral Therapy and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2003
- Lopinavir Plasma Concentrations and Changes in Lipid Levels During Salvage Therapy with Lopinavir/Ritonavir-Containing RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Impact of HIV Infection and HAART on Serum Lipids in MenJAMA, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapyAIDS, 2001
- High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from framingham to the veterans affairs high-density lipoprotein intervention trialThe American Journal of Cardiology, 2000